

# Press Release

Abliva AB (publ), 556595-6538  
20 June 2022 10:00:00 CEST - Lund,  
Sweden



---

## Spots left: Abliva's Fireside Chat in Lund and Stockholm

**Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, invites interested shareholders and investors to an informal "Fireside Chat" with the company's CEO, Ellen Donnelly, and members of the Abliva team, in Lund (today, 20 June) and Stockholm (tomorrow, 21 June).**

In light of our recent announcement and the continued developments in the company, we would like to invite shareholders and interested investors to an informal gathering to hear more about the path forward directly from Ellen Donnelly (CEO) and the Abliva team. We hope you will join us in Lund or Stockholm during the Midsummer week to hear an update on the company, learn more about the ongoing rights issue, and ask your most pressing questions. The event is free of charge, and wine and snacks will be served. As seats are limited, please respond quickly to reserve your space.

**Lund, today 20 June, 16:00 – 18:00 p.m. CEST:**

Restaurant Inspira, Medicon Village, Scheeletorget 1.

**Stockholm, tomorrow 21 June, 16:00 – 18:00 p.m. CEST:**

Erik Penser Bank, Apelbergsgatan 27.

Please respond to [anmalan@abliva.com](mailto:anmalan@abliva.com) to reserve your space.

Watch the interview with CEO Ellen Donnelly by #InvestTalks, June 13, 2022: <https://youtu.be/CT8cL1LVF1w>.

**For more information, please contact:**

---

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations  
+46 (0)46-275 62 21, [ir@abliva.com](mailto:ir@abliva.com)

**Abliva AB (publ)**

Medicon Village, SE-223 81 Lund, Sweden  
Tel: +46 (0)46 275 62 20 (switchboard)  
[info@abliva.com](mailto:info@abliva.com), [www.abliva.com](http://www.abliva.com)

Subscribe to our news: <https://abliva.com/posts/news-subscription/>

Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>

Subscribe to our YouTube channel: <https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg>

**Abliva AB (publ)** - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol ABLI.

# Press Release

Abliva AB (publ), 556595-6538  
20 June 2022 10:00:00 CEST - Lund,  
Sweden



---

## **Abliva – Delivering mitochondrial health**

---

Abliva discovers and develops medicines for the treatment of primary mitochondrial diseases. These rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD<sup>+</sup> and NADH, is entering late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

## **Attachments**

---

[Spots left: Abliva's Fireside Chat in Lund and Stockholm](#)